Skip to content
Screener

Xencor XNCR Stock-Based Comp

Stock-Based Comp at other companies

Amgen logo
AmgenAMGN
$165M+5.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$243M-3.5%
Janux Therapeutics logo
Janux TherapeuticsJANX
$3.78M-31.2%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$12.29M-13.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$14.22M+55.0%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$575.57K-33.7%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization5,0075,346
Accretion of discount on marketable debt securities, net(135)(1,489)
Stock-based compensation18,75322,950
Loss (gain) on sale of marketable securities, net2(5,380)
Change in fair value of marketable equity securities33,865(528)
Asset impairment charges7976,723
Non-cash royalty revenue related to the sale of future royalties(17,201)(36,831)

Item 1. Financial Statements

FAQ

What is Xencor's stock-based comp?
Xencor (XNCR) reported stock-based comp of $4.51M in Q2 2026.
How has Xencor's stock-based comp changed year-over-year?
Xencor's stock-based comp increased by 3.9% year-over-year, from $4.34M to $4.51M.
What is the long-term trend for Xencor's stock-based comp?
Over 4 years (2021 to 2025), Xencor's stock-based comp has grown at a -0.1% compound annual growth rate (CAGR), from $36.98M to $36.83M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Xencor's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude